Lantern Pharma Inc.LTRNNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank86
3Y CAGR+14.9%
5Y CAGR+42.2%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+14.9%/yr
vs +96.9%/yr prior
5Y CAGR
+42.2%/yr
Recent deceleration
Acceleration
-82.1pp
Decelerating
Percentile
P86
Within normal range
vs 5Y Ago
5.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
PeriodValueYoY Change
TTM$13.04M-19.1%
2024$16.13M+35.6%
2023$11.89M+38.3%
2022$8.60M+13.6%
2021$7.57M+237.5%
2020$2.24M+135.3%
2019$953185.00+66.6%
2018$572095.00-